WO2003025138A3 - Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer - Google Patents

Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer Download PDF

Info

Publication number
WO2003025138A3
WO2003025138A3 PCT/US2002/029560 US0229560W WO03025138A3 WO 2003025138 A3 WO2003025138 A3 WO 2003025138A3 US 0229560 W US0229560 W US 0229560W WO 03025138 A3 WO03025138 A3 WO 03025138A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
cancer
diagnosis
modulators
screening
Prior art date
Application number
PCT/US2002/029560
Other languages
French (fr)
Other versions
WO2003025138A2 (en
Inventor
Daniel Afar
Natasha Aziz
Kurt C Gish
Peter A Hevezi
David H Mack
Keith E Wilson
Albert Zlotnik
Original Assignee
Eos Biotechnology Inc
Daniel Afar
Natasha Aziz
Kurt C Gish
Peter A Hevezi
David H Mack
Keith E Wilson
Albert Zlotnik
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eos Biotechnology Inc, Daniel Afar, Natasha Aziz, Kurt C Gish, Peter A Hevezi, David H Mack, Keith E Wilson, Albert Zlotnik filed Critical Eos Biotechnology Inc
Priority to EP02766297A priority Critical patent/EP1434881A4/en
Priority to CA002459219A priority patent/CA2459219A1/en
Priority to AU2002330039A priority patent/AU2002330039A1/en
Priority to JP2003529912A priority patent/JP2005518782A/en
Publication of WO2003025138A2 publication Critical patent/WO2003025138A2/en
Publication of WO2003025138A3 publication Critical patent/WO2003025138A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Abstract

Described herein are genes whose expression are up-regulated or down-regulated in specific cancers. Related methods and compositions that can be used for diagnosis and treatment of those cancers are disclosed. Also described herein are methods that can be used to identify modulators of selected cancers.
PCT/US2002/029560 2001-09-17 2002-09-17 Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer WO2003025138A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP02766297A EP1434881A4 (en) 2001-09-17 2002-09-17 Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer
CA002459219A CA2459219A1 (en) 2001-09-17 2002-09-17 Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer
AU2002330039A AU2002330039A1 (en) 2001-09-17 2002-09-17 Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer
JP2003529912A JP2005518782A (en) 2001-09-17 2002-09-17 Cancer diagnosis method, cancer modulator screening composition and method

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US32346901P 2001-09-17 2001-09-17
US60/323,469 2001-09-17
US32388701P 2001-09-20 2001-09-20
US60/323,887 2001-09-20
US35066601P 2001-11-13 2001-11-13
US60/350,666 2001-11-13
US35514502P 2002-02-08 2002-02-08
US35525702P 2002-02-08 2002-02-08
US60/355,145 2002-02-08
US60/355,257 2002-02-08
US37224602P 2002-04-12 2002-04-12
US60/372,246 2002-04-12

Publications (2)

Publication Number Publication Date
WO2003025138A2 WO2003025138A2 (en) 2003-03-27
WO2003025138A3 true WO2003025138A3 (en) 2003-05-08

Family

ID=27559718

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/029560 WO2003025138A2 (en) 2001-09-17 2002-09-17 Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer

Country Status (5)

Country Link
EP (1) EP1434881A4 (en)
JP (1) JP2005518782A (en)
AU (1) AU2002330039A1 (en)
CA (1) CA2459219A1 (en)
WO (1) WO2003025138A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9562049B2 (en) 2012-12-21 2017-02-07 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US9567340B2 (en) 2012-12-21 2017-02-14 Medimmune Limited Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases

Families Citing this family (135)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6986201A (en) 2000-06-16 2002-01-02 Biogen Inc Renal regulatory elements and methods of use thereof
US20060035237A1 (en) 2002-08-26 2006-02-16 Markowitz Sanford D Methods and compositions for categorizing patients
US8981061B2 (en) 2001-03-20 2015-03-17 Novo Nordisk A/S Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
DE60224275T2 (en) 2001-06-01 2008-12-11 Biogen Idec Ma Inc., Cambridge MOLECULES AND METHOD FOR INHIBITING THE RELEASE OF KIM-1
WO2003027320A2 (en) * 2001-09-24 2003-04-03 University Of Aarhus Methods for diagnosis and treatment of diseases associated with altered expression of pik3r1
US20050123925A1 (en) 2002-11-15 2005-06-09 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
DE60220621T2 (en) 2001-11-09 2008-03-06 Proteologics, Inc. Posh nucleic acid, polypeptides and related methods
AU2003228336B2 (en) * 2002-03-19 2009-07-30 Curagen Corporation Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2003087408A2 (en) * 2002-04-05 2003-10-23 University Court Of The University Of Edinburgh Schizophrenia associated genes
AU2003278137A1 (en) 2002-06-20 2004-01-06 Bristol-Myers Squibb Company Identification and regulation of a g-protein coupled receptor, rai-3
GB0215224D0 (en) * 2002-07-01 2002-08-14 Inpharmatica Ltd Protein
MXPA05005036A (en) * 2002-11-12 2005-07-01 Wyeth Corp A novel pth responsive gene.
AU2003299925B2 (en) 2002-12-30 2011-10-27 Biogen Ma Inc. KIM-1 antagonists and use to modulate immune system
JP4462964B2 (en) * 2003-03-10 2010-05-12 第一三共株式会社 Antibodies targeting cancer-specific antigens
EP1615991A4 (en) 2003-04-03 2007-12-19 Bristol Myers Squibb Co Polynucleotide encoding a novel human p2x7 splice variant, hbmyp2x7v
EP1923401A3 (en) * 2003-04-14 2008-08-20 Novartis AG Gene expression associated with osteoblast differentiation
EP1623230A2 (en) * 2003-05-05 2006-02-08 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor gpr39 (gpr39)
WO2005001049A2 (en) * 2003-06-06 2005-01-06 Diadexus, Inc. Compositions, splice variants and methods relating to ovarian specific genes and proteins
US7294704B2 (en) 2003-08-15 2007-11-13 Diadexus, Inc. Pro108 antibody compositions and methods of use and use of Pro108 to assess cancer risk
SG149815A1 (en) 2003-11-06 2009-02-27 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
US20050153352A1 (en) * 2004-01-09 2005-07-14 Stanley Chang Cancer specific gene MG20
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
GB0404209D0 (en) * 2004-02-25 2004-03-31 Uws Ventures Ltd Materials and methods for treatment of allergic disease
ATE459883T1 (en) 2004-02-27 2010-03-15 Inst Curie NEW PROLIFERATION MARKERS IN CLINICAL PRACTICE AND THEIR USE FOR CANCER PROGNOSIS OR DIAGNOSIS
US8124730B1 (en) 2004-04-02 2012-02-28 Bristol-Myers Squibb Company Polynucleotide encoding a novel human P2X7 splice variant, HBMYP2X7v
JP4685767B2 (en) 2004-04-27 2011-05-18 武田薬品工業株式会社 Novel ligand of G protein-coupled receptor protein and its use
WO2005108997A1 (en) * 2004-05-11 2005-11-17 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with dipeptidyl-peptidase 6 (dpp6)
MXPA06014065A (en) 2004-06-01 2007-01-31 Genentech Inc Antibody drug conjugates and methods.
US8604185B2 (en) 2004-07-20 2013-12-10 Genentech, Inc. Inhibitors of angiopoietin-like 4 protein, combinations, and their use
AU2005269716B2 (en) 2004-07-20 2011-01-27 Genentech, Inc. Inhibitors of angiopoietin-like 4 protein, combinations, and their use
ZA200701184B (en) 2004-07-20 2008-07-30 Genentech Inc Compositions and methods of using angiopoietin-like 4 protein
CN101065151B (en) 2004-09-23 2014-12-10 健泰科生物技术公司 Cysteine engineered antibodies and conjugates
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
GB0426146D0 (en) 2004-11-29 2004-12-29 Bioxell Spa Therapeutic peptides and method
AU2006218489B2 (en) 2005-03-02 2011-02-24 Biogen Ma Inc. KIM-1 antibodies for treatment of Th2-mediated conditions
CA2604515A1 (en) * 2005-04-18 2006-10-26 The Provost, Fellows And Scholars Of The College Of The Holy And Undivid Ed Trinity Of Queen Elizabeth, Near Dublin Toll-like receptor 14 (tlr14 ) and use thereof
WO2007008647A2 (en) * 2005-07-07 2007-01-18 Vanderbilt University Diagnosing and grading gliomas using a proteomics approach
WO2007064696A2 (en) * 2005-11-29 2007-06-07 Nevada Cancer Institute Targeting of sall4 for the treatment and diagnosis of proliferative disorders associated with myelodysplastic syndrome (mds)
PL1957539T3 (en) 2005-12-08 2013-08-30 Squibb & Sons Llc Human monoclonal antibodies to protein tyrosine kinase 7 (ptk7) and their use
AR059432A1 (en) 2006-02-10 2008-04-09 Genentech Inc ANTI-FGF19 ANTIBODIES AND METHODS USING THESE
PL1989231T3 (en) 2006-03-21 2015-10-30 Genentech Inc Combinatorial therapy involving alpha5beta1 antagonists
WO2008054534A2 (en) 2006-05-11 2008-05-08 Quark Pharmaceuticals, Inc. Screening systems utilizing rtp801
WO2007141796A2 (en) 2006-06-09 2007-12-13 Quark Pharmaceuticals, Inc. Therapeutic uses of inhibitors of rtp801l
US7851144B2 (en) 2006-08-18 2010-12-14 The University Of Washington Compositions and methods for detecting cancer
GB0620695D0 (en) * 2006-10-18 2006-11-29 Opsona Therapeutics Composition and methods for the treatment of nurdegenerative disease
GB0620705D0 (en) 2006-10-18 2006-11-29 Opsona Therapeutics Compounds for the modulation of toll-like receptor activity and assay methods for the identification of said compounds
EP1932854A1 (en) * 2006-12-15 2008-06-18 Institut National De La Sante Et De La Recherche Medicale (Inserm) Lysosomal associated membrane protein (LAMP) - like polypeptide, ligands to the same, and use of the same in the frame of detection and purification of human plasmacytoid dendritic cells
EP2377952A1 (en) * 2007-04-26 2011-10-19 Ludwig Institute For Cancer Research Methods for diagnosing and treating astrocytomas
JP5352586B2 (en) * 2007-07-27 2013-11-27 イマティクス バイオテクノロジーズ ゲーエムベーハー Composition of tumor-related peptides and related anti-cancer vaccines
US8236307B2 (en) 2007-08-03 2012-08-07 Genentech, Inc. Humanized anti-FGF19 antagonists and methods using same
CA2736170A1 (en) 2007-09-06 2009-03-12 Case Western Reserve University Methods for diagnosing and treating cancers
AU2008304452B2 (en) 2007-09-26 2014-01-16 Genentech, Inc. Novel antibodies
US8614311B2 (en) 2007-12-12 2013-12-24 Quark Pharmaceuticals, Inc. RTP801L siRNA compounds and methods of use thereof
WO2010002862A2 (en) 2008-07-01 2010-01-07 Aveo Pharmaceuticals, Inc. Fibroblast growth factor receptor 3 (fgfr3) binding proteins
CA2727915C (en) 2008-07-15 2016-04-26 Genentech, Inc. Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds
US20110160085A1 (en) * 2008-08-25 2011-06-30 Katherine Li Biomarkers for anti-tnf treatment in ulcreative colitis and related disorders
WO2010047310A1 (en) 2008-10-20 2010-04-29 大日本住友製薬株式会社 Tumor antigen peptide and use thereof
AU2014201027B2 (en) * 2008-12-08 2015-11-19 Compugen Ltd. FAM26F polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
CA2745492A1 (en) 2008-12-08 2010-06-17 Compugen Ltd. A polyclonal or monoclonal antibody or antibody binding fragment that binds to a tmem154 polypeptide
SG10201609416XA (en) 2009-03-25 2016-12-29 Genentech Inc NOVEL ANTI-α5ß1 ANTIBODIES AND USES THEREOF
IN2012DN03025A (en) 2009-09-09 2015-07-31 Ct Se Llc
US9127071B2 (en) 2010-01-29 2015-09-08 Chugai Seiyaku Kabushiki Kaisha Anti-DLL3 antibody
AR080243A1 (en) 2010-02-23 2012-03-21 Genentech Inc COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TUMOR TREATMENT
EA024730B1 (en) 2010-04-15 2016-10-31 Медимьюн Лимитед Pyrrolobenzodiazepine compounds, conjugates thereof, pharmaceutical compositions comprising said conjugates, and use of said conjugates
KR101839163B1 (en) 2010-06-08 2018-03-15 제넨테크, 인크. Cysteine engineered antibodies and conjugates
WO2012074757A1 (en) 2010-11-17 2012-06-07 Genentech, Inc. Alaninyl maytansinol antibody conjugates
CA2833212C (en) 2011-05-12 2020-06-09 Genentech, Inc. Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature peptides
KR101877598B1 (en) 2011-10-14 2018-07-11 메디뮨 리미티드 Pyrrolobenzodiazepines and conjugates thereof
US9550830B2 (en) 2012-02-15 2017-01-24 Novo Nordisk A/S Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
EP3196214B1 (en) 2012-02-15 2019-07-31 Novo Nordisk A/S Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (trem-1)
SI2814842T1 (en) 2012-02-15 2018-10-30 Novo Nordisk A/S Antibodies that bind peptidoglycan recognition protein 1
WO2013130093A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
RU2015106946A (en) 2012-08-02 2016-09-27 Дженентек, Инк. ANTIBODIES TO TYPE B ENDOTHELIN RECEPTOR (ETBR) AND THEIR IMMUNO CONJUGATES
EP2879708A4 (en) 2012-08-02 2016-03-16 Genentech Inc Anti-etbr antibodies and immunoconjugates
ES2680153T3 (en) 2012-10-12 2018-09-04 Adc Therapeutics Sa Anti-PSMA-pyrrolobenzodiazepine antibody conjugates
EP2906251B1 (en) 2012-10-12 2017-09-27 ADC Therapeutics SA Pyrrolobenzodiazepine-anti-cd22 antibody conjugates
EP2906296B1 (en) 2012-10-12 2018-03-21 ADC Therapeutics SA Pyrrolobenzodiazepine-antibody conjugates
HUE042731T2 (en) 2012-10-12 2019-07-29 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
LT2839860T (en) 2012-10-12 2019-07-10 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US10695433B2 (en) 2012-10-12 2020-06-30 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
TR201815418T4 (en) 2012-10-12 2018-11-21 Adc Therapeutics Sa Pyrrolobenzodiazepine -anti-psma antibody conjugates.
CA2905181C (en) 2013-03-13 2020-06-02 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof for providing targeted therapy
US9821074B2 (en) 2013-03-13 2017-11-21 Genentech, Inc. Pyrrolobenzodiazepines and conjugates thereof
KR102066318B1 (en) 2013-03-13 2020-01-14 메디뮨 리미티드 Pyrrolobenzodiazepines and conjugates thereof
DK2970473T3 (en) 2013-03-14 2017-11-27 Bristol Myers Squibb Co COMBINATION OF DR5 AGONIST AND ANTI-PD-1 ANTAGONIST AND METHODS FOR USING IT
TWI636792B (en) 2013-08-12 2018-10-01 建南德克公司 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
WO2015052535A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
WO2015052532A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
WO2015052534A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
CN107106700B (en) 2013-12-16 2020-10-30 基因泰克公司 Peptidomimetic compounds and antibody-drug conjugates thereof
CN105828840B (en) 2013-12-16 2020-08-04 基因泰克公司 1- (chloromethyl) -2, 3-dihydro-1H-benzo [ e ] indole dimer antibody-drug conjugate compounds and methods of use and treatment
JP6671292B2 (en) 2013-12-16 2020-03-25 ジェネンテック， インコーポレイテッド Peptidomimetic compounds and antibody-drug conjugates thereof
JP6738316B2 (en) 2014-07-17 2020-08-12 ノヴォ ノルディスク アクティーゼルスカブ Site-directed mutagenesis of TREM-1 antibody to reduce viscosity
WO2016037644A1 (en) 2014-09-10 2016-03-17 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
EP3191521A2 (en) 2014-09-12 2017-07-19 F. Hoffmann-La Roche AG Cysteine engineered antibodies and conjugates
CN106714844B (en) 2014-09-12 2022-08-05 基因泰克公司 Anthracycline disulfide intermediates, antibody-drug conjugates and methods
EP3235820A1 (en) 2014-09-17 2017-10-25 Genentech, Inc. Pyrrolobenzodiazepines and antibody disulfide conjugates thereof
AU2015352545B2 (en) 2014-11-25 2020-10-15 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
WO2016090050A1 (en) 2014-12-03 2016-06-09 Genentech, Inc. Quaternary amine compounds and antibody-drug conjugates thereof
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
MA43345A (en) 2015-10-02 2018-08-08 Hoffmann La Roche PYRROLOBENZODIAZEPINE ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
MA43354A (en) 2015-10-16 2018-08-22 Genentech Inc CONJUGATE DRUG CONJUGATES WITH CLOUDY DISULPHIDE
MA45326A (en) 2015-10-20 2018-08-29 Genentech Inc CALICHEAMICIN-ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
CN108700598A (en) 2016-03-25 2018-10-23 豪夫迈·罗氏有限公司 The drug of the total antibody of multichannel and antibody conjugate quantifies measuring method
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
PL3458101T3 (en) 2016-05-20 2021-05-31 F. Hoffmann-La Roche Ag Protac antibody conjugates and methods of use
EP3465221B1 (en) 2016-05-27 2020-07-22 H. Hoffnabb-La Roche Ag Bioanalytical method for the characterization of site-specific antibody-drug conjugates
JP7043425B2 (en) 2016-06-06 2022-03-29 ジェネンテック， インコーポレイテッド Silvestrol Antibodies-Drug Conjugates and Usage
EP3496763A1 (en) 2016-08-11 2019-06-19 Genentech, Inc. Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
JP7050770B2 (en) 2016-10-05 2022-04-08 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Method for preparing antibody drug conjugate
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
LT3544636T (en) 2017-02-08 2021-06-25 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
EP3612537B1 (en) 2017-04-18 2022-07-13 Medimmune Limited Pyrrolobenzodiazepine conjugates
WO2018193102A1 (en) 2017-04-20 2018-10-25 Adc Therapeutics Sa Combination therapy with an anti-axl antibody-drug conjugate
UA127900C2 (en) 2017-06-14 2024-02-07 Ейдісі Терапьютікс Са Dosage regimes for the administration of an anti-cd19 adc
MX2020001880A (en) 2017-08-18 2021-07-06 Medimmune Ltd Pyrrolobenzodiazepine conjugates.
WO2019060398A1 (en) 2017-09-20 2019-03-28 Ph Pharma Co., Ltd. Thailanstatin analogs
JP7314146B2 (en) 2017-12-28 2023-07-25 中外製薬株式会社 Cytotoxicity-inducing therapeutic agent
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
US11155618B2 (en) 2018-04-02 2021-10-26 Bristol-Myers Squibb Company Anti-TREM-1 antibodies and uses thereof
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
EP3870235A1 (en) 2018-10-24 2021-09-01 F. Hoffmann-La Roche AG Conjugated chemical inducers of degradation and methods of use
CN113227119A (en) 2018-12-10 2021-08-06 基因泰克公司 Photocrosslinked peptides for site-specific conjugation to Fc-containing proteins
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
CN115397866A (en) 2020-03-31 2022-11-25 中外制药株式会社 DLL 3-targeted multispecific antigen-binding molecules and uses thereof
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
CN114113603B (en) * 2021-06-30 2023-11-17 四川大学华西医院 Application of CYTL1 as gastric cancer prognosis marker

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6194158B1 (en) * 1998-11-12 2001-02-27 Nyxis Neurotherapies, Inc. Diagnostic assay for cancer
US6426186B1 (en) * 2000-01-18 2002-07-30 Incyte Genomics, Inc Bone remodeling genes
US6500938B1 (en) * 1998-01-30 2002-12-31 Incyte Genomics, Inc. Composition for the detection of signaling pathway gene expression

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6500938B1 (en) * 1998-01-30 2002-12-31 Incyte Genomics, Inc. Composition for the detection of signaling pathway gene expression
US6194158B1 (en) * 1998-11-12 2001-02-27 Nyxis Neurotherapies, Inc. Diagnostic assay for cancer
US6440676B1 (en) * 1998-11-12 2002-08-27 Nyxis Neurotherapies, Inc. Diagnostic assay for cancer
US6426186B1 (en) * 2000-01-18 2002-07-30 Incyte Genomics, Inc Bone remodeling genes

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of EP1434881A4 *
SMYTH TEMPLETON ET AL.: "Cloning and characterization of human tumor cell", INSTERSTITIAL COLLAGENASE, vol. 50, no. 17, September 1990 (1990-09-01), pages 5431 - 5437, XP000652150 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9562049B2 (en) 2012-12-21 2017-02-07 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US9567340B2 (en) 2012-12-21 2017-02-14 Medimmune Limited Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases

Also Published As

Publication number Publication date
WO2003025138A2 (en) 2003-03-27
EP1434881A4 (en) 2005-10-26
EP1434881A2 (en) 2004-07-07
JP2005518782A (en) 2005-06-30
CA2459219A1 (en) 2003-03-27
AU2002330039A1 (en) 2003-04-01

Similar Documents

Publication Publication Date Title
WO2003025138A3 (en) Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer
WO2002059377A3 (en) Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer
WO2002102235A3 (en) Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
WO2002030268A3 (en) Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer
WO2003042661A3 (en) Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
WO2003003906A3 (en) Diagnostic and screening methods for bladder cancer
WO2004063355A3 (en) Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of matastatic cancer
WO2004048938A3 (en) Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators
WO2002098358A3 (en) Methods of diagnosis and treatment of androgen-dependent prostate cancer, prostate cancer undergoing androgen-withdrawal, and androgen-independent prostate cancer
WO2004073657A3 (en) Methods of diagnosis of cancer and other diseases, composition and methods of screening for modulators of cancer and other diseases
WO2004070062A3 (en) Compositions and methods for diagnosing and treating cancers
WO2006113483A3 (en) Methods and compositions for treating or preventing cancer
AU2001229340A1 (en) Genes compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
WO2004113571A3 (en) Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis
WO2004058171A3 (en) Antibodies against gpr64 and uses thereof
AU2001241541A1 (en) Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer
WO2003008583A3 (en) Novel compositions and methods for cancer
AU2001265296A1 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
WO2004106495A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
AU2002251366A1 (en) Proteins, genes and their use for diagnosis and treatment of breast cancer
AU2001252945A1 (en) Compositions and methods for therapy and diagnosis of colon cancer
WO2002021996A3 (en) Methods of diagnosis of colorectal cancer, compositions and methods of screening for colorectal cancer modulators
WO2005003154A8 (en) Compositions and methods for the diagnosis and treatment of tumor
AU2001240909A1 (en) Proteins, genes and their use for diagnosis and treatment of breast cancer
AU2003217774A1 (en) Method and composition for detection and treatment of breast cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG US

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2459219

Country of ref document: CA

Ref document number: 2003529912

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002766297

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002766297

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2002766297

Country of ref document: EP